These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32860346)

  • 21. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
    Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
    J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
    Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
    JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A scoring evaluation for the practical introduction of guideline-directed medical therapy in heart failure patients.
    Matsukawa R; Okahara A; Tokutome M; Itonaga J; Koga E; Hara A; Kisanuki H; Sada M; Okabe K; Kawai S; Ogawa K; Matsuura H; Mukai Y
    ESC Heart Fail; 2023 Dec; 10(6):3352-3363. PubMed ID: 37671603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice.
    Smith KV; Dunning JR; Fischer CM; MacLean TE; Bosque-Hamilton JW; Fera LE; Grant JY; Zelle DJ; Matta L; Gaziano TA; MacRae CA; Scirica BM; Desai AS
    J Pharm Pract; 2022 Oct; 35(5):747-751. PubMed ID: 33813934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: An analysis from the Swedish Heart Failure Registry.
    Schrage B; Lund LH; Benson L; Braunschweig F; Ferreira JP; Dahlström U; Metra M; Rosano GMC; Savarese G
    Eur J Heart Fail; 2023 Jul; 25(7):1132-1144. PubMed ID: 37317585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low blood pressure and guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
    Izumi K; Kohno T; Goda A; Takeuchi S; Shiraishi Y; Saji M; Nagatomo Y; Tanaka TD; Takei M; Nakano S; Soejima K; Kohsaka S; Yoshikawa T;
    Int J Cardiol; 2023 Jan; 370():255-262. PubMed ID: 36270494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal Heart Failure Medical Therapy and Mortality in Survivors of Cardiogenic Shock: Insights From the FRENSHOCK Registry.
    Matsushita K; Delmas C; Marchandot B; Roubille F; Lamblin N; Leurent G; Levy B; Elbaz M; Champion S; Lim P; Schneider F; Khachab H; Carmona A; Trimaille A; Bourenne J; Seronde MF; Schurtz G; Harbaoui B; Vanzetto G; Biendel C; Labbe V; Combaret N; Mansourati J; Filippi E; Maizel J; Merdji H; Lattuca B; Gerbaud E; Bonnefoy E; Puymirat E; Bonello L; Morel O
    J Am Heart Assoc; 2024 Mar; 13(5):e030975. PubMed ID: 38390813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation.
    Higuchi S; Orban M; Adamo M; Giannini C; Melica B; Karam N; Praz F; Kalbacher D; Koell B; Stolz L; Braun D; Näbauer M; Wild M; Doldi P; Neuss M; Butter C; Kassar M; Ruf T; Petrescu A; Ludwig S; Pfister R; Iliadis C; Unterhuber M; Sampaio F; Ferreira D; Thiele H; Baldus S; von Bardeleben RS; Massberg S; Windecker S; Lurz P; Petronio AS; Lindenfeld J; Abraham WT; Metra M; Hausleiter J;
    Eur J Heart Fail; 2022 Nov; 24(11):2152-2161. PubMed ID: 35791663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guideline directed medical therapy and reduction of secondary mitral regurgitation.
    Spinka G; Bartko PE; Heitzinger G; Prausmüller S; Winter MP; Arfsten H; Strunk G; Rosenhek R; Kastl S; Hengstenberg C; Pavo N; Hülsmann M; Goliasch G
    Eur Heart J Cardiovasc Imaging; 2022 Jun; 23(6):755-764. PubMed ID: 35466372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescription Rates and Prognostic Implications of Optimally Targeted Guideline-Directed Medical Treatment in Heart Failure and Atrial Fibrillation: Insights From The MISOAC-AF Trial.
    Moysidis DV; Kartas A; Samaras A; Papazoglou AS; Patsiou V; Bekiaridou A; Baroutidou A; Tsagkaris C; Karagiannidis E; Daios S; Anastasiou V; Tsalikakis D; Efthimiadis G; Ziakas A; Tzikas A; Giannakoulas G
    J Cardiovasc Pharmacol; 2023 Mar; 81(3):203-211. PubMed ID: 36626410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.
    Fiuzat M; Schulte PJ; Felker M; Ahmad T; Neely M; Adams KF; Donahue MP; Kraus WE; Piña IL; Whellan DJ; O'Connor CM
    J Card Fail; 2014 Jan; 20(1):38-44. PubMed ID: 24304938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry.
    Lainščak M; Milinković I; Polovina M; Crespo-Leiro MG; Lund LH; Anker SD; Laroche C; Ferrari R; Coats AJS; McDonagh T; Filippatos G; Maggioni AP; Piepoli MF; Rosano GMC; Ruschitzka F; Simić D; Ašanin M; Eicher JC; Yilmaz MB; Seferović PM;
    Eur J Heart Fail; 2020 Jan; 22(1):92-102. PubMed ID: 31863522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction.
    Hamada T; Kubo T; Kawai K; Nakaoka Y; Yabe T; Furuno T; Yamada E; Kitaoka H;
    ESC Heart Fail; 2023 Feb; 10(1):223-233. PubMed ID: 36193578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineralocorticoid receptor antagonist use following heart failure hospitalization.
    Duran JM; Gad S; Brann A; Greenberg B
    ESC Heart Fail; 2020 Apr; 7(2):482-492. PubMed ID: 32035000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-year mortality and readmission rates in patients with heart failure in India: Results from the Trivandrum heart failure registry.
    Harikrishnan S; Jeemon P; Ganapathi S; Agarwal A; Viswanathan S; Sreedharan M; Vijayaraghavan G; Bahuleyan CG; Biju R; Nair T; Pratapkumar N; Krishnakumar K; Rajalekshmi N; Suresh K; Huffman MD
    Int J Cardiol; 2021 Mar; 326():139-143. PubMed ID: 33049297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
    Ferreira JP; Rossignol P; Machu JL; Sharma A; Girerd N; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Lang CC; Ter Maaten JM; Metra M; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Voors A; Zannad F
    Eur J Heart Fail; 2017 Oct; 19(10):1284-1293. PubMed ID: 28580625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).
    Vaduganathan M; Dei Cas A; Mentz RJ; Greene SJ; Khan S; Subacius HP; Chioncel O; Maggioni AP; Konstam MA; Senni M; Fonarow GC; Butler J; Gheorghiade M;
    Am J Cardiol; 2014 Sep; 114(5):743-50. PubMed ID: 25060414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
    Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
    Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.